Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. “The Submarine Study”
Eye, Published online: 03 August 2023; doi:10.1038/s41433-023-02676-9Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. “The Submarine Study” (Source: Eye)
Source: Eye - August 3, 2023 Category: Opthalmology Authors: Matias Iglicki Marina Khoury Lucas Donato Diego Jose Quispe Hermino Pablo Negri Javier Ignacio Melamud Source Type: research
Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials
Conclusions
Anti-VEGF therapy is effective and well-tolerated for myopia CNV patients. Anti-VEGF retreatment guided by disease activity criteria can achieve comparable efficacy and potentially reduce anti-VEGF injections.
PROSPERO registration number
CRD42021292806. (Source: BMJ Open)
Source: BMJ Open - July 20, 2023 Category: General Medicine Authors: Dong, L., Li, G., Song, Z., Cheng, X., Bai, J., Zhang, C. Tags: Open access, Ophthalmology Source Type: research
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
CONCLUSION: Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.PMID:37461836 | DOI:10.1177/11206721231187663 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 18, 2023 Category: Opthalmology Authors: Argyrios Chronopoulos Elisa Huynh Agharza Ashurov James S Schutz Jost B Jonas Lars-Olof Hattenbach Source Type: research
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
CONCLUSION: Our results suggest a favourable anatomical and visual response after treatment switch to brolucizumab in patients with nAMD refractory to previous anti-VEGF agents.PMID:37461836 | DOI:10.1177/11206721231187663 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 18, 2023 Category: Opthalmology Authors: Argyrios Chronopoulos Elisa Huynh Agharza Ashurov James S Schutz Jost B Jonas Lars-Olof Hattenbach Source Type: research
Exudation in Patients with Neovascular Age-Related Macular Degeneration Treated with the Port Delivery System or Monthly Injections
Vascular endothelial growth factor-A (VEGF-A) is a critical stimulus for neovascularization (NV) and excessive vascular leakage resulting in exudation and reduced vision in patients with neovascular age-related macular degeneration (nAMD). 1 Monthly injections of ranibizumab or injections of aflibercept every other month control exudation in most patients and provide substantial improvement in vision.2-4 Observational studies have demonstrated that in clinical practice injection frequency of anti-VEGF agents in patients with nAMD is substantially lower than that in clinical trials and visual outcomes are much worse. (Sourc...
Source: American Journal of Ophthalmology - July 13, 2023 Category: Opthalmology Authors: Anam Akhlaq, David Williams, W. Lloyd Clark, Hannah Khan, Arshad M. Khanani, Lisa Walden, Carl Awh, J. Taylor Graff, Jordan M. Graff, Taku Wakabayashi, Carl Regillo, Katie F. Maass, Natalia Callaway, Shamika Gune, Peter A. Campochiaro Tags: Original Articles Source Type: research
